October 2011

Joyce A. O'Shaughnessy explores the 8th Annual School of Breast Oncology, an interactive program designed to immerse oncology professionals in the latest science.

Newly-diagnosed asymptomatic follicular lymphoma patients with low tumor burden can have their initial treatment delayed.

Ezra E. W. Cohen, MD, has focused on the role of EGFR inhibitors in much of his research into head and neck cancers.

The level of C-reactive protein (CRP) expressed in the tumor specimens of patients with renal cell carcinoma (RCC) may serve as a widely available biomarker for postoperative prognosis of localized disease.

The impact that the tumor microenvironment has on the survival and growth of cancer cells is becoming increasingly well defined on several fronts.

The Z11 study suggests that there is no difference in survival among patients with breast cancer who did not undergo a recommended surgical treatment.

This year marks more than 20 years of research into the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway.

If IKK kinase, a group of inhibitory proteins, activity is not regulated properly, tumors in the body have the ability to migrate and proliferate.

The scientific strategy of attacking cancer by thwarting angiogenesis has been on a roller coaster ride for the past 40 years

Josep Tabernero, MD, is actively involved in clinical research with molecular targeted therapies, with a focus on EGFR-family and PI3K-Akt-mTOR pathway inhibitors, in phase II and III studies with new chemotherapy agents in gastrointestinal tumors.

There are at least 7 drugs specifically targeting VEGF in later-stage clinical trials that have been the subject of presentations at oncology conferences in recent months.

Ezra E. W. Cohen, MD, is a physician and translational researcher at the University of Chicago Medical Center, that focuses on epidermal growth factor receptor (EGFR) inhibitors.

A panel released guidelines to help clinicians identify patients experiencing cancer-related pain who would benefit from an implanted intrathecal (IT) drug delivery systems.

ASCO endorses a Canadian agency's outlook on ovarian ablation, chemotherapy limits for stage IV lung cancer patients, and supportive care antiemetic therapies.

One of the more unique aspects of cancer chemotherapy is the relatively frequent development of serious, even severe, adverse effects.